Follows the Recent Appointment of Ryan Confer as Genprex President and CEO and to
its Board of Directors
AUSTIN,
Texas, May 13, 2024 /PRNewswire/ -- Genprex,
Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage
gene therapy company focused on developing life-changing therapies
for patients with cancer and diabetes, today announced that the
Board of Directors has appointed Jose A.
Moreno Toscano as non-executive Chairman of the Board
following the sudden passing of the Company's co-founder and
previous Chairman Rodney Varner.
Prior to his appointment as Chairman, Mr. Moreno Toscano has served on Genprex's Board of
Directors since March 2020. Since
April 2018, Mr. Moreno Toscano
has been Chief Executive Officer of LFB USA Inc, the US subsidiary of LFB Group, a
global integrated biopharmaceutical company, and he has more than
20 years of experience in the pharmaceutical and biotechnology
industries, building, developing and transforming organizations.
Mr. Moreno Toscano has a successful
track record of identifying and capitalizing on opportunities to
drive exponential revenue growth and market expansion, revitalizing
underperforming operations and establishing foundations for
successful start-up operations. His experience includes strategic
planning, corporate restructuring, business development, M&A,
investor relations and general management.
Mr. Moreno Toscano's appointment
follows the recent appointment of Ryan
Confer to serve as Genprex's President and Chief Executive
Officer. Mr. Confer was also appointed to Genprex's Board of
Directors.
Mr. Moreno Toscano commented:
"On behalf of Genprex's Board of Directors, we wish to express
our support for Ryan as Genprex's new President and Chief Executive
Officer. We have worked closely with Ryan over the last several
years, and we have seen his robust leadership skills and
exceptional operational organization. He has strengthened the
company's operational and financial foundation, bolstered the
company's talent and culture, added value in every company
department and has continuously advanced the company's strategies
year after year. I look forward to working alongside Ryan and our
other fellow directors in my role as Chairman in what I believe
will be a transformational time for Genprex."
About Genprex, Inc.
Genprex, Inc. is a clinical-stage
gene therapy company focused on developing life-changing therapies
for patients with cancer and diabetes. Genprex's technologies are
designed to administer disease-fighting genes to provide new
therapies for large patient populations with cancer and diabetes
who currently have limited treatment options. Genprex works with
world-class institutions and collaborators to develop drug
candidates to further its pipeline of gene therapies in order to
provide novel treatment approaches. Genprex's oncology program
utilizes its systemic, non-viral Oncoprex® Delivery System which
encapsulates the gene-expressing plasmids using lipid-based
nanoparticles in a lipoplex form. The resultant product is
administered intravenously, where it is taken up by tumor cells
that then express tumor suppressor proteins that were deficient in
the tumor. The Company's lead product candidate, Reqorsa®
Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated
in three clinical trials as a treatment for NSCLC and SCLC. Each of
Genprex's three lung cancer clinical programs has received a Fast
Track Designation from the FDA for the treatment of that patient
population, and Genprex's SCLC program has received an FDA Orphan
Drug Designation. Genprex's diabetes gene therapy approach is
comprised of a novel infusion process that uses an AAV vector to
deliver Pdx1 and MafA genes directly to the pancreas. In models of
Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas
into functional beta-like cells, which can produce insulin but may
be distinct enough from beta cells to evade the body's immune
system. In a similar approach, GPX-002 for Type 2 diabetes, where
autoimmunity is not at play, is believed to rejuvenate and
replenish exhausted beta cells.
Interested investors and shareholders are encouraged to sign up
for press releases and industry updates by visiting
the Company Website, registering for Email
Alerts and by following Genprex on Twitter, Facebook and
LinkedIn.
Cautionary Language Concerning Forward-Looking
Statements
Statements contained in this press release
regarding matters that are not historical facts are
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements are made on the basis of the current beliefs,
expectations and assumptions of management, are not guarantees of
performance and are subject to significant risks and uncertainty.
These forward-looking statements should, therefore, be considered
in light of various important factors, including those set forth in
Genprex's reports that it files from time to time with the
Securities and Exchange Commission and which you should review,
including those statements under "Item 1A – Risk Factors" in
Genprex's Annual Report on Form 10-K for the year ended
December 31, 2023.
Because forward-looking statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding:
the appointment and transition of management personnel and other
succession plan-related activities; Genprex's ability to advance
the clinical development, manufacturing and commercialization of
its product candidates in accordance with projected timelines and
specifications; the timing and success of Genprex's clinical trials
and regulatory approvals; the effect of Genprex's product
candidates, alone and in combination with other therapies, on
cancer and diabetes; Genprex's future growth and financial status,
including Genprex's ability to maintain compliance with the
continued listing requirements of The Nasdaq Capital Market and to
continue as a going concern and to obtain capital to meet its
long-term liquidity needs on acceptable terms, or at all; Genprex's
commercial and strategic partnerships, including those with its
third party vendors, suppliers and manufacturers and their ability
to successfully perform and scale up the manufacture of its product
candidates; and Genprex's intellectual property and licenses.
These forward-looking statements should not be relied upon as
predictions of future events and Genprex cannot assure you that the
events or circumstances discussed or reflected in these statements
will be achieved or will occur. If such forward-looking statements
prove to be inaccurate, the inaccuracy may be material. You should
not regard these statements as a representation or warranty by
Genprex or any other person that Genprex will achieve its
objectives and plans in any specified timeframe, or at all. You are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release.
Genprex disclaims any obligation to publicly update or release any
revisions to these forward-looking statements, whether as a result
of new information, future events or otherwise, after the date of
this press release or to reflect the occurrence of unanticipated
events, except as required by law.
Genprex, Inc.
(877) 774-GNPX (4679)
GNPX Investor Relations
investors@genprex.com
GNPX Media Contact
Kalyn
Dabbs
media@genprex.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/genprex-announces-the-appointment-of-jose-a-moreno-toscano-as-chairman-of-the-board-of-directors-302142996.html
SOURCE Genprex, Inc.